Expanding Myelofibrosis Treatment: The Role of Momelotinib

During a roundtable discussion at the 66th American Society of Hematology Annual Meeting & Exposition, Dr. Prithviraj Bose, MD, of MD Anderson Cancer Center, Francesca Palandri, MD, PhD, of Università di Bologna, Andrew Kuykendall, MD, of Moffitt Cancer Center, and Lucia Masarova, MD, of MD Anderson Cancer Center explore the clinical development of momelotinib for the treatment of myelofibrosis. The discussion focuses on how momelotinib provides new therapeutic options for patients moving beyond ruxolitinib treatment and examines the differences in its clinical use and adoption in the United States versus Europe. These esteemed experts provide valuable insights into the evolving treatment landscape and its implications for patient care.